BrainStorm Cell To Announce Top Line Results From The U.S. Phase 2 Study of NurOwn In Patients With Amyotrophic Lateral Sclerosis (ALS) On Monday, July 18

HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of NurOwn® in Patients with ALS on Monday, July 18, 2016. The Company will host a conference call and webcast with slides at 10:00am Eastern Time.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn®technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn®has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company’s website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

Logo - http://photos.prnewswire.com/prnh/20141006/150511

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-to-announce-top-line-results-from-the-us-phase-2-study-of-nurown-in-patients-with-amyotrophic-lateral-sclerosis-als-on-monday-july-18-300299078.html

SOURCE BrainStorm Cell Therapeutics Inc.